Novartis presents new data on early symptom relief and long-term control in complex skin diseases at AAD 2026

• New Rhapsido^® REMIX-1 & -2 pooled analysis on symptom control as early as week 1 in chronic spontaneous urticaria (CSU) to be presented
  
  
• Long-term Cosentyx^® data build on extensive body of evidence supporting continuous use in hidradenitis suppurativa (HS) and psoriasis
  
  
• Additional Cosentyx data in HS include indirect comparison of efficacy and safety vs bimekizumab

Basel, March 23, 2026 – Novartis will present data from more than 20 abstracts from its growing immunology portfolio at this year’s American Academy of Dermatology (AAD) Annual Meeting.

Presentations include new Rhapsido^® (remibrutinib) data highlighting changes in daily itch and hives severity scores at week 1 in patients with chronic spontaneous urticaria (CSU), an indirect comparison on Cosentyx^® (secukinumab) safety and flare prevention for patients with hidradenitis suppurativa (HS) vs. bimekizumab, as well as 4- and 5-year efficacy data from pivotal trials in HS and psoriasis, respectively.

“Novartis data at this year’s AAD build on the robust body of evidence for the use of Rhapsido and Cosentyx in their approved dermatological indications,” said Angelika Jahreis, Global Head, Immunology Development, Novartis. “These presentations also demonstrate the strength of our immunology portfolio and our ongoing efforts to help patients manage chronic diseases that significantly impact their lives and overall well-being.”

Key abstracts accepted by AAD include:

Molecule/disease state	Abstract title	Abstract number/ presentation details
Rhapsido® (remibrutinib)
CSU	Early symptom improvement with remibrutinib in chronic spontaneous urticaria: Daily Itch Severity Scores and Hives Severity Scores from phase 3 REMIX-1/-2 studies	Abstract #71668 e-Poster & Oral Presentation March 27, 3:15 pm MT
	Design of the REASSERT Study: A prospective, multi-country, noninterventional effectiveness and safety study evaluating remibrutinib in patients worldwide with chronic spontaneous urticaria (CSU)	Abstract #72973 e-Poster March 27
Burden of disease
	Urticaria Voices: Treatment patterns and disease control in patients with self-reported chronic inducible urticaria	Abstract #75145 e-Poster March 27
Cosentyx® (secukinumab)
HS	Flare prevention and safety of secukinumab vs bimekizumab in hidradenitis suppurativa: A matched adjusted indirect comparison analysis of Phase 3 trials	Abstract #76852 e-Poster & Oral Presentation Mar 27, 1:45 pm MT
	Designing a secukinumab dosing regimen in adolescents with moderate to severe hidradenitis suppurativa using model-informed drug development	Abstract #74494 e-Poster & Oral Presentation March 28, 2:00 pm MT
	Four-year efficacy of continuous secukinumab in SUNSHINE/SUNRISE core and extension trials on hidradenitis suppurativa (HS) lesions	Abstract #75099 e-Poster March 27
Psoriatic arthritis	Effectiveness of Secukinumab in Preventing Psoriatic Arthritis in Patients With Moderate to Severe Psoriasis	Abstract #73859 e-Poster & Oral Presentation March 28, 11:45 am MT
	Impact of Disease Duration on the Treatment Effect of Secukinumab in the Prevention of Psoriatic Arthritis in Patients with Moderate to Severe Psoriasis: A 5-year Pooled Analysis of the ERASURE, FIXTURE and SCULPTURE Studies	Abstract #74500 e-Poster & Oral Presentation March 28, 2:05 pm MT

About Novartis Immunology
At Novartis, we’re advancing bold science with the goal of bringing relief and a renewed sense of hope to people living with autoimmune diseases. Building on our legacy of first-in-class innovation across rheumatology, dermatology and allergy, and a diverse industry-leading pipeline, we’re committed to shaping what’s next in Immunology.

Product Information
For full prescribing information, including approved indications and important safety information about marketed products, please visit https://www.novartis.com/about/products.

Disclaimer
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “potential,” “can,” “will,” “plan,” “may,” “could,” “would,” “expect,” “anticipate,” “look forward,” “believe,” “committed,” “investigational,” “pipeline,” “launch,” or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this press release, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Novartis
Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 300 million people worldwide.

Reimagine medicine with us: Visit us at https://www.novartis.com and connect with us on LinkedIn, Facebook, X/Twitter and Instagram.

# # #

Novartis Media Relations E-mail: media.relations@novartis.com
Novartis Investor Relations Central investor relations line: +41 61 324 7944 E-mail: investor.relations@novartis.com